Brokers Offer Predictions for SAGE Q1 Earnings

Sage Therapeutics, Inc. (NASDAQ:SAGE) – Leerink Partnrs issued their Q1 2025 earnings per share estimates for Sage Therapeutics in a research note issued on Tuesday, February 11th. Leerink Partnrs analyst M. Goodman expects that the biopharmaceutical company will earn ($1.03) per share for the quarter. The consensus estimate for Sage Therapeutics’ current full-year earnings is ($6.46) per share. Leerink Partnrs also issued estimates for Sage Therapeutics’ Q2 2025 earnings at ($0.99) EPS and Q4 2025 earnings at ($0.98) EPS.

A number of other equities research analysts also recently issued reports on the stock. Canaccord Genuity Group reduced their price target on shares of Sage Therapeutics from $9.00 to $8.00 and set a “hold” rating on the stock in a research note on Wednesday. Oppenheimer decreased their price target on Sage Therapeutics from $9.00 to $8.00 and set a “market perform” rating on the stock in a research note on Wednesday, October 30th. Truist Financial cut their price objective on Sage Therapeutics from $13.00 to $8.00 and set a “hold” rating on the stock in a report on Wednesday, October 30th. TD Cowen lowered their target price on Sage Therapeutics from $10.00 to $9.00 and set a “hold” rating for the company in a report on Thursday, November 21st. Finally, Piper Sandler dropped their target price on Sage Therapeutics from $26.00 to $9.00 and set an “overweight” rating for the company in a research report on Thursday, January 2nd. Three analysts have rated the stock with a sell rating, sixteen have given a hold rating and two have assigned a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $9.65.

Sage Therapeutics Price Performance

NASDAQ SAGE opened at $7.16 on Thursday. The stock has a market capitalization of $437.98 million, a P/E ratio of -1.28 and a beta of 0.94. The firm’s 50-day moving average is $6.34 and its two-hundred day moving average is $6.93. Sage Therapeutics has a 12 month low of $4.62 and a 12 month high of $27.39.

Sage Therapeutics (NASDAQ:SAGE) last announced its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported ($1.56) EPS for the quarter, missing the consensus estimate of ($1.54) by ($0.02). Sage Therapeutics had a negative net margin of 317.29% and a negative return on equity of 50.29%.

Hedge Funds Weigh In On Sage Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SAGE. Wells Fargo & Company MN boosted its holdings in shares of Sage Therapeutics by 27.3% in the 4th quarter. Wells Fargo & Company MN now owns 33,051 shares of the biopharmaceutical company’s stock valued at $179,000 after buying an additional 7,087 shares in the last quarter. ExodusPoint Capital Management LP acquired a new position in Sage Therapeutics in the fourth quarter valued at $759,000. Geode Capital Management LLC grew its holdings in shares of Sage Therapeutics by 1.1% during the fourth quarter. Geode Capital Management LLC now owns 1,256,903 shares of the biopharmaceutical company’s stock worth $6,827,000 after purchasing an additional 14,049 shares during the last quarter. Fox Run Management L.L.C. grew its holdings in shares of Sage Therapeutics by 199.0% during the fourth quarter. Fox Run Management L.L.C. now owns 48,950 shares of the biopharmaceutical company’s stock worth $266,000 after purchasing an additional 32,579 shares during the last quarter. Finally, KLP Kapitalforvaltning AS acquired a new stake in shares of Sage Therapeutics during the fourth quarter worth about $49,000. 99.22% of the stock is owned by institutional investors and hedge funds.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.